Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I8/502

[1] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南(2015版)[J]. 中华肝脏病杂志, 2015, 23(11):810-820.
[2] Paudel R, Dogra P, Suman S, et al. Acute liver and renal failure: A rare adverse effect exclusive to intravenous form of amiodarone[J]. Case Reports in Critical Care, 2016,2016(12):1-4.
[3] 李莉, 杨俊,丁家望, 等.胺碘酮致急性肝损伤一例[J]. 中华心血管病杂志, 2008, 36(5):464.
[4] 中华医学会心血管病学分会, 中国生物医学工程学会心律分会, 胺碘酮抗心律失常治疗应用指南工作组. 胺碘酮抗心律失常治疗应用指南(2008)[J]. 中华心血管病杂志, 2008, 36(9):769-777.
[5] Kumar S, Bangalore S, Kumari R, et al. Amiodarone-induced acute respiratory distress syndrome masquerading as acute heart failure[J]. The Journal of Emergency Medicine, 2012, 43(5):e311-e314.
[6] 黄兴福, 杨艳敏,朱俊, 等. 静脉胺碘酮的主要不良反应分析[J]. 中国心脏起搏与心电生理杂志, 2007, 21(6):485-488.
[7] 张满娣. 盐酸胺碘酮致严重急性肝损害1例[J]. 中国药物警戒, 2009,6(10):630.
[8] 张战文, 赵智琛, 刘沙, 等.静脉应用胺碘酮致严重肝功能衰竭一例[J].中国心血管病研究, 2012,10(6):477-478.
[9] 韦志军, 黄桂波, 蓝四海, 等.胺碘酮致低血压及严重肝损害一例[J].华夏医学, 2012,25(1):96-97,125.
[10] Gluck N, Fried M, Porat R.Acute amiodarone liver toxicity likely due to ischemic hepatitis[J]. Isr Med Assoc J, 2011, 13(12):748-752.
[11] Nasser M, Larsen T R, Waanbah B, et al. Hyperacute drug-induced hepatitis with intravenous amiodarone: Case report and review of the literature[J]. Drug Healthc Patient Saf, 2013, 5:191-198.
[12] Ratz Bravo AE, Drewe J, Schlienger RG, et al. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature[J]. Crit Care Med, 2005, 33(1):128-134.
[13] 郝建, 彭晓露, 陆学丹, 等. 老年慢性阻塞性肺疾病患者伴肺性缺氧与肝功能损害的相关性研究[J]. 实用老年医学, 2008, 22(1):46-48.
[14] Rhodes A, Eastwood J B, Smith S A. Early acute hepatitis with parenteral amiodarone: A toxic effect of the vehicle[J]. Gut, 1993, 34(4):565-566.
[15] 毛敏, 徐小华, 赵嘉澍, 等. 60例静脉滴注盐酸胺碘酮致急性肝损害病例分析[J]. 中国药物警戒, 2015, 12(6):347-351.
[16] James P R, Hardman S M. Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy[J]. Heart,1997,77(6):583-583.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.